

**MD Anderson-Determined Financial Conflict(s) of Interest
for Senior/key Personnel Working on a Research Project with an Award Date after Aug. 23, 2012**

<u>PI</u>	<u>Title/Role</u>	<u>Entity with Conflict</u>	<u>Sponsor</u>	<u>Nature of SFI (Type)</u>	<u>Dollar and range of SFI</u>
Amin, Hesham	Principal Investigator	Novatek Therapeutics	Novatek Therapeutics	Ownership Interest	Equity valued at less than \$10,000
Andreeff, Michael	Principal Investigator	Brooklyn ImmunoTherapeutics	Brooklyn ImmunoTherapeutics	Equity for scientific advising	Equity value: \$25,000 - \$50,000
Andreeff, Michael	Principal Investigator	Senti Biosciences	Senti Biosciences	Equity for scientific advising	Not readily determined (not publicly traded)
Andreeff, Michael	Principal Investigator	Oncoceutics	Oncoceutics	Equity for scientific advising	Not readily determined (equity in private start up)
Bedford, Mark	Principal Investigator	EpiCypher	NIH	License and equity	Not readily determined (equity in private start up)
Chemaly, Roy	Principal Investigator	Merck	Merck	Compensation for scientific advising and speaking	Compensation is between \$50,000 - \$100,000
Chemaly, Roy	Principal Investigator	Oxford Immunotec	Oxford Immunotec	Compensation for consulting	Compensation is between \$25,000 - \$50,000
Cleeland, Charles	Principal Investigator	Symptom Assessment Systems	Bayer Pharma	Ownership and license agreement	50% ownership of SAS
Cressman, Erik	Principal Investigator	Thunar Medical, Inc.	Thunar Medical, Inc.	Ownership Interest	Not readily determined (equity in private start up)
Curran, Michael	Co-Investigator	Molecular Templates	Molecular Templates	Ownership interest	Equity valued at under \$10,000.
Curran, Michael	Principal Investigator	Immunogenesis	Immunogenesis	Compensation and equity for scientific advising	Compensation is between \$25,000 - \$50,000 + equity. Value of equity is not readily determined (not publicly traded)
Curran, Michael	Principal Investigator	OncoResponse	OncoResponse	Equity for scientific advising	Not readily determined (not publicly traded)
Dinardo, Courtney	Principal Investigator	Notable Labs	Notable Labs	Equity for consulting services	Not readily determined (not publicly traded)
Fokt, Izabela	Investigator	CNS Pharmaceuticals	CNS Pharmaceuticals	License and equity	Equity : value between than \$200,000 - \$249,999.
Fueyo, Juan	Principal Investigator	DNAtrix	American Brain Tumor Association	License and equity	Not readily determined (equity in private start up)
Fueyo, Juan	Principal Investigator	DNAtrix	Cancer Prevention Research Institute of Texas	License and equity	Not readily determined (equity in private start up)
Fueyo, Juan	Principal Investigator	DNAtrix	DNAtrix	License and equity	Not readily determined (equity in private start up)
Fueyo, Juan	Principal Investigator	DNAtrix	MD Anderson Cancer Center - Moonshot	License and equity	Not readily determined (equity in private start up)
Fueyo, Juan	Co-Investigator	DNAtrix	National Institutes of Health	License and equity	Not readily determined (equity in private start up)

**MD Anderson-Determined Financial Conflict(s) of Interest
for Senior/key Personnel Working on a Research Project with an Award Date after Aug. 23, 2012**

Fueyo, Juan	Principal Investigator	DNatrix	National Institutes of Health	License and equity	Not readily determined (equity in private start up)
Fueyo, Juan	Principal Investigator	DNatrix	Department of Defense	License and equity	Not readily determined (equity in private start up)
Gibbons, Don	Principal Investigator	Ribon Therapeutisc	Ribon Therapeutics	License and equity	Not readily determined (equity in private start up)
Gomez-Manzano, Candelaria	Principal Investigator	DNatrix	MD Anderson Cancer Center - Moonshot	License and equity	Not readily determined (equity in private start up)
Gomez-Manzano, Candelaria	Principal Investigator	DNatrix	Department of Defense	License and equity	Not readily determined (equity in private start up)
Gomez-Manzano, Candelaria	Co-Investigator	DNatrix	National Institutes of Health	License and equity	Not readily determined (equity in private start up)
Gomez-Manzano, Candelaria	Principal Investigator	DNatrix	Cancer Prevention Research Institute of Texas	License and equity	Not readily determined (equity in private start up)
Hart, Glen Traver	Principal Investigator	Blueline Biosciences (Repare)	Blueline Biosciences (Repare)	Compensation and equity for scientific advising	Compensation is between: \$20,000 - \$50,000; Equity valued between \$600,000 - \$649,999
Hazle, John	Principal Investigator	Imagion Biosystems	Imagion Biosystems	Equity ownership	Equity value: \$25,000 - \$50,000
Hwang, Rosa	Principal Investigator	StellaNova	StellaNova	License and equity, Compensation for consulting	Equity value: not readily determined (equity in a private start up) Compensation for consulting is between \$20,000 - \$50,000
Janku, Filip	Principal Investigator	ImmunoMet	ImmunoMet	Compensation for consulting	Compensation is between \$50,000 - \$100,000
Jenq, Robert	Principal Investigator	Kaleido Biosciences	Kaleido Biosciences	Equity for consulting services	Equity value: \$100,000 - \$150,000
Jiang, Wen	Principal Investigator	Spot BioSystems	Spot Biosystems	Equity for scientific advising (family member)	Not readily determined (equity in private start up)
Kalluri, Raghu	Principal Investigator	Codiak Biosciences	Codiak Biosciences	License, equity and Board of Directors.	Not readily determined (equity in private start up)
Kopetz, Scott	Principal Investigator	Navire Pharma	Navire Pharma	Compensation and equity for scientific advising	Compensation is between \$20,000 - \$50,000; Equity value is not readily determined (not publicly traded)
Lin, Steven	Principal Investigator	STCube	STCube	License, equity and scientific advisor	Not readily determined (equity in private start up)
Ma, Qing	Principal Investigator	CLS Therapeutics	CLS Therapeutics	Compensation for consulting and scientific advising	Compensation is between \$20,000 - \$50,000
Mazur, Pawel	Principal Investigator	Ikena Oncology	Ikena Oncology	Equity ownership	Equity: value greater than \$1,000,000.

**MD Anderson-Determined Financial Conflict(s) of Interest
for Senior/key Personnel Working on a Research Project with an Award Date after Aug. 23, 2012**

Ng, Chaan	Principal Investigator	General Electric	General Electric	Compensation for consulting and scientific advising	Compensation is between \$20,000 - \$50,000
Orlowski, Robert	Principal Investigator	Asylia Therapeutics	Asylia Therapeutics	Compensation for scientific advising	Compensation is between \$50,000 - \$100,000 + equity. Value of equity is not readily determined (not publicly traded)
Priebe, Waldemar	Principal Investigator	CNS Pharmaceuticals	CNS Pharmaceuticals	License and equity	Equity : value greater than \$1,000,000.
Priebe, Waldemar	Principal Investigator	Houston Pharmaceuticals	Houston Pharmaceuticals	Equity ownership	Not readily determined (equity in private start up)
Priebe, Waldemar	Principal Investigator	Moleculin	NIH	Equity, license and consultant	Compensation is between \$50,000 - \$100,000 + equity. Equity : value greater than \$1,000,000.
Priebe, Waldemar	Principal Investigator	Moleculin	Moleculin	Equity, license and consultant	Compensation is between \$50,000 - \$100,000 + equity. Equity : value greater than \$1,000,000.
Reisner, Yair	Principal Investigator	Cell Source	Cancer Prevention Research Institute of Texas	License and equity	Equity valued between \$600,000 - \$649,999
Reisner, Yair	Principal Investigator	Cell Source	Cell Source	License and equity	Equity valued between \$600,000 - \$649,999
Reuben, James	Principal Investigator	Angle North America	Angle North America	Compensation for scientific advising	Compensation is between \$20,000 - \$50,000
Roth, Jack	Principal Investigator	Convergen Life Sciences (Genprex)	Convergen Life Sciences (Genprex)	Compensation and equity for consulting	Compensation is between \$150,000 - \$199,999; Equity is valued over \$600,000
Roth, Jack	Principal Investigator	Convergen Life Sciences (Genprex)	NIH	Compensation and equity for consulting	Compensation is between \$150,000 - \$199,999; Equity is valued over \$600,000
Sampath, D	Principal Investigator	Newave Pharmaceutical	Newave Pharmaceutical	Compensation and equity for scientific advising	Not readily determined (not publicly traded)
Sharma, Padmanee	Principal Investigator	Constellation Pharmaceuticals	Constellation Pharmaceuticals	Equity for scientific advising	Not readily determined (not publicly traded)
Sokolov, Konstantin	Principal Investigator - subaward	Nanohybrids	NCI	License and equity	Not readily determined (equity in private start up)
Smith, Benjamin	Principal Investigator	Oncora Medical	Oncora Medical	License and equity	Not readily determined (equity in private start up)

**MD Anderson-Determined Financial Conflict(s) of Interest
for Senior/key Personnel Working on a Research Project with an Award Date after Aug. 23, 2012**

Smith, Grace	Principal Investigator	Oncora Medical	Oncora Medical	License equity (spouse)	Not readily determined (equity in private start up)
Symmans, William	Principal Investigator	Delphi Diagnostics	Breast Cancer Research Foundation	License and equity	Not readily determined (equity in private start up)
Symmans, William	Principal Investigator	Delphi Diagnostics	Cancer Prevention Research Institute of Texas	License and equity	Not readily determined (equity in private start up)
Tweardy, David	Principal Investigator	Tvardi Therapeutics	NIH	License and equity	Not readily determined (equity in private start up)
Tweardy, David	Principal Investigator	Tvardi Therapeutics	Cancer Prevention Research Institute of Texas	License and equity	Not readily determined (equity in private start up)
Ueno, Naoto	Principal Investigator	Ourotech LTD	Ourotech LTD	Equity for scientific advising services	Not readily determined (equity in private start up)
Welsh, James	Principal Investigator	Checkmate Pharmaceuticals	Checkmate Pharmaceuticals	Equity for consulting services	Not readily determined (not publicly traded)
Welsh, James	Principal Investigator	MolecularMatch	MolecularMatch	License and ownership interest	Not readily determined (not publicly traded)
Welsh, James	Principal Investigator	Reflexion	Reflexion	Equity for scientific advising services	Not readily determined (not publicly traded)
Wistuba, Ignacio	Principal Investigator	Genentech	Genentech	Compensation for consulting and scientific advising	Compensation is between \$20,000 - \$50,000
Wood, Richard	Principal Investigator	Blueline Biosciences (Repare)	Blueline Biosciences (Repare)	Equity for consulting services	Equity valued between \$600,000 - \$649,999
Yee, Cassian	Principal Investigator	Berkeley Lights	Berkeley Lights	Equity and compensation for scientific advising	Compensation is between \$50,000 - \$100,000 + equity. Value of equity is not readily determined (not publicly traded)
Yee, Cassian	Principal Investigator	Immatics Biotechnologies	Immatics Biotechnologies	Equity and compensation for scientific advising	Compensation is between \$50,000 - \$100,000 + equity. Value of equity is not readily determined (not publicly traded)
Zielinski, Rafal	Investigator	Moleculin LLC	Moleculin LLC	License and ownership interest	Value of equity is not readily determined